Overexpression of HER2 is a frequent molecular alteration in GC, which is currently an FDA‐approved biomarker to guide first‐line targeted therapy for inoperable locally advanced, recurrent, or metastatic gastric adenocarcinoma.3 Here, ERBB2 is linked to gastric cancer.